D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Shrikhande, Shailesh V ^a   Barreto, Savio G ^a   Talole, Sanjay D ^a   Vinchurkar, Kumar ^a   Annaiah, Somashekar ^a   Suradkar, Kunal ^a   Mehta, Shaesta ^a   Goel, Mahesh ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

D2 lymphadenectomy; Gastrectomy; Gastric cancer; Morbidity; Mortality; Neoadjuvant chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; OXALIPLATIN;

ACUTE DIARRHEA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CHICKENPOX; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LENGTH OF STAY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRIMARY TUMOR; PROSPECTIVE STUDY; SAFETY; SKIN TOXICITY; STOMACH ADENOCARCINOMA; SURGICAL MORTALITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84873049141     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-31     Document Type: Article

References (29)

1. Rajdev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 2010, 11:14-23. 10.1007/s11864-010-0117-1, 20358316.
2. Shrikhande S, Upasani V, Mehta S, Shukla PJ, Mohandas VV. Recent advances in gastric cancer. Recent Advances in Surgery 2006, 269-281. New Delhi: Jaypee Publishing, Gupta RL.
3. Dikshit R, Gupta P, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, Kumar R, Roy S, Suraweera W, Bray F, Mallath M, Singh PK, Sinha DN, Shet AS, Gelband H, Jha P, . Million Death Study Collaborators Cancer mortality in India: a nationally representative survey. Lancet 2012, 379:1807-1816. 10.1016/S0140-6736(12)60358-4, 22460346, Million Death Study Collaborators.
4. Sarker SK, Sinha VK, Chaudhry R, Maudar KK. Gastric cancer: a critical analysis of surgical treatment and long term survival. J Indian Med Assoc 1992, 90:61-64.
5. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999, 230:170-178. 10.1097/00000658-199908000-00006, 1420871, 10450730.
6. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996, 347:995-999. 10.1016/S0140-6736(96)90144-0, 8606613.
7. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J ClinOncol 2004, 22:2767-2773.
8. Shrikhande SV, Shukla PJ, Qureshi S, Siddachari R, Upasani V, Ramadwar M, Kakade AC, Hawaldar R. D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials. Dig Surg 2006, 23:192-197. 10.1159/000094537, 16837811.
9. D'Souza MA, Singh K, Shrikhande SV. Surgery for gastric cancer: an evidence-based perspective. J Cancer Res Ther 2009, 5:225-231. 10.4103/0973-1482.59891, 20160354.
10. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, . MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer. N Engl J Med 2006, 355:11-20. 10.1056/NEJMoa055531, 16822992, MAGIC Trial Participants.
11. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectablegastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J ClinOncol 2011, 29:1715-1721.
12. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J ClinOncol 2010, 28:5210-5218.
13. An J, Kim K, Kim Y, Cheong JH, Hyung WJ, Noh SH. Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance. Ann SurgOncol 2012, 19:2452-2458.
14. Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann SurgOncol 2007, 14:2010-2017.
15. Valenti V, Hernandez-Lizoain JL, Beorlegui MC, Diaz-Gozalez JA, Regueira FM, Rodriguez JJ, Viudez A, Sola I, Cienfuegos JA. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J SurgOncol 2011, 104:124-129.
16. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, . Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46. 10.1056/NEJMoa073149, 18172173, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom.
17. Okines A, Norman A, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009, 20:1529-1534. 10.1093/annonc/mdp047, 19474114.
18. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
19. Japanese Gastric Cancer A Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998, 1:10-24. Japanese Gastric Cancer A.
20. Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011, 14:113-123. Japanese Gastric Cancer Association.
21. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006, 93:559-563. 10.1002/bjs.5353, 16607678.
22. Wente MN, Bassi C, Dervenis C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Yeo CJ, Buchler MW. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007, 142:761-768. 10.1016/j.surg.2007.05.005, 17981197.
23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004, 240:205-213. 10.1097/01.sla.0000133083.54934.ae, 1360123, 15273542.
24. Edge S, Byrd D, Compton C, Fritz A. (Eds): AJCC Cancer Staging Manual 2009, New York: Springer Verlag, 7.
25. Wu Z, Teng R, Shen J, Xie SD, Xu CY, Wang LB. Reduced lymph node harvest after neoadjuvant chemotherapy in gastric cancer. J Int Med Res 2011, 39:2086-2095.
26. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, Lui WY, Whang-Peng J. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006, 7:309-315. 10.1016/S1470-2045(06)70623-4, 16574546.
27. Deodhar K, Budukh A, Ramadwar M, Bal MM, Shrikhande SV. Are we achieving the benchmark of retrieving 12 lymph nodes in colorectal carcinoma specimens? Experience from a tertiary referral centre in India and review of literature.Indian. J PatholMicrobiol 2012, 55:38-42.
28. Shrikhande S, Barreto S, Somashekar B, Suradkar K, Shetty GS, Talole S, Sirohi B, Goel M, Shukla PJ. Evolution of pancreatoduodenectomy in a tertiary cancer centre in India: improved results from service reconfiguration. Pancreatology 2012,
29. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Staging laparoscopy for gastric cancer. Diagnostic laparoscopy guidelines 2007, Los Angeles, CA: SAGES, http://www.sages.org/publication/id/12/, Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).